Citations

Clear

626 citation(s) found for "Mehta, SH".

Survey and Evaluation of Hypertension Machine Learning Research
Toit, Clea du , Tran, Tran , Deo, Neha , Aryal, Sachin , Lip, Stefanie , Sykes, Robert , Manandhar, Ishan , Sionakidis, Aristeidis , Pattnaik, Harsha , Alsanosi, Safaa , Kassi, Maria, Lê, Ngọc Minh, Rostron, Maggie , Nichol, Sarah , Mehta, Dhruven , Tummala, Ramakumar , Reddy, Sandeep , Visweswaran, Shyam , Joe, Bina , Le, Nhu Ngoc , du Toit, Clea , Tran, Tran Quoc Bao , Pattnaik, Harsha , Alsanosi, Safaa , Rostron, Maggie , Nichol, Sarah , Aman, Alisha , Nawaz, Faisal A , Mehta, Dhruven , Tummala, Ramakumar , McCallum, Linsay , Reddy, Sandeep , Visweswaran, Shyam , Kashyap, Rahul , Joe, Bina , Padmanabhan, Sandosh , Deo, Neha N , Stevenson, Leah, Nawaz, Faisal A. , Kashyap, Rahul , Padmanabhan, Sandosh

Mayo Clinic

Journal of the American Heart Association | April 29, 2023 | Volume: 12 | Issue: 9 | Pages: No page available

10.1161/jaha.122.027896 | PMID 37119074 Get It

Background Machine learning (ML) is pervasive in all fields of research, from automating tasks to complex decision‐making. However, applications in different specialities are variable and generally limited. Like other conditions, the number of studies employing ML in hypertension research is growing rapidly. In this study, we aimed to survey hypertension research using ML, evaluate the reporting quality, and identify barriers to ML's potential to transform hypertension care. Methods and Results The Harmonious Understanding of Machine Learning Analytics Network survey questionnaire was applied to 63 hypertension‐related ML research articles published between January 2019 and September 2021. The most common research topics were blood pressure prediction (38%), hypertension (22%), cardiovascular outcomes (6%), blood pressure variability (5%), treatment response (5%), and real‐time blood pressure estimation (5%). The reporting quality of the articles was variable. Only 46% of articles described the study population or derivation cohort. Most articles (81%) reported at least 1 performance measure, but only 40% presented any measures of calibration. Compliance with ethics, patient privacy, and data security regulations were mentioned in 30 (48%) of the articles. Only 14% used geographically or temporally distinct validation data sets. Algorithmic bias was not addressed in any of the articles, with only 6 of them acknowledging risk of bias. Conclusions Recent ML research on hypertension is limited to exploratory research and has significant shortcomings in reporting quality, model validation, and algorithmic bias. Our analysis identifies areas for improvement that will help pave the way for the realization of the potential of ML in hypertension and facilitate its adoption.
Low Clinical Sensitivity and Unexpectedly High Incidence for Neuropathologically Diagnosed Progressive Supranuclear Palsy (PSP) (S51.001)
Driver‐Dunckley, Erika , Dunckley, Nathaniel, Sue, Lucia I., Shill, Holly A. , Mehta, Shyamal H. , Belden, Christine M. , Beach, Thomas G. , Zhang, Nan , Serrano, Geidy E. , Tremblay, Cécilia , Atri, Alireza , Adler, Charles H.

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202619 Get It

Characteristics and Treatment Response to OnabotulinumtoxinA of Patients From CD-PROBE With Anterocollis and Retrocollis (P12-11.005)
Mehta, Shyamal H. , Sadeghi, Marjan, Dashtipour, Khashayar , Jankovic, Joseph J. , Charles, David , Schwartz, Marc

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202586 Get It

Delayed Onset ICANS Leading to Bilateral Cranial Neuropathies: Two Case Reports (P12-13.005)
Beck, Kelsey, Hasan, Shemonti , Mehta, Shyamal H. , Sánchez, Cristina Valencia

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202192 Get It

Cerebral white matter rarefaction has both neurodegenerative and vascular causes and may primarily be a distal axonopathy
Beach, Thomas G. , Sue, Lucia I., Scott, Sarah, Intorcia, Anthony J., Walker, Jessica E. , Arce, Richard, Glass, Michael J. , Borja, Claryssa I., Cline, Madison P. , Hemmingsen, Spencer J, Qiji, Sanaria H., Stewart, Analisa M. , Martinez, Kayleigh N, Krupp, Addison, McHattie, Rylee, Mariner, Monica, Lorenzini, Ileana , Kuramoto, Angela, Long, Kathy E., Tremblay, Cécilia , Caselli, Richard J. , Woodruff, Bryan K. , Rapscak, Steven Z., Belden, Christine M. , Goldfarb, Danielle, Driver‐Dunckley, Erika , Mehta, Shyamal H. , Shill, Holly A. , Driver-Dunckley, Erika D., Adler, C H , Choudhury, Parichita , Sabbagh, Marwan Noel , Atri, Alireza , Adler, Charles H. , Serrano, Geidy E.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | April 18, 2023 | Volume: 82 | Issue: 6 | Pages: 457-466

10.1093/jnen/nlad026 | PMID 37071794 Get It

Abstract Cerebral white matter rarefaction (CWMR) was considered by Binswanger and Alzheimer to be due to cerebral arteriolosclerosis. Renewed attention came with CT and MR brain imaging, and neuropathological studies finding a high rate of CWMR in Alzheimer disease (AD). The relative contributions of cerebrovascular disease and AD to CWMR are still uncertain. In 1181 autopsies by the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND), large-format brain sections were used to grade CWMR and determine its vascular and neurodegenerative correlates. Almost all neurodegenerative diseases had more severe CWMR than the normal control group. Multivariable logistic regression models indicated that Braak neurofibrillary stage was the strongest predictor of CWMR, with additional independently significant predictors including age, cortical and diencephalic lacunar and microinfarcts, body mass index, and female sex. It appears that while AD and cerebrovascular pathology may be additive in causing CWMR, both may be solely capable of this. The typical periventricular pattern suggests that CWMR is primarily a distal axonopathy caused by dysfunction of the cell bodies of long-association corticocortical projection neurons. A consequence of these findings is that CWMR should not be viewed simply as “small vessel disease” or as a pathognomonic indicator of vascular cognitive impairment or vascular dementia.
Etiologies and Outcome of Patients with Solid Tumors Admitted to ICU with Acute Respiratory Failure: A Secondary Analysis of the EFRAIM Study
Benguerfi, Soraya , Soares, Márcio , Meert, Anne‐Pascale , Martín‐Loeches, Ignacio , Mehta, Sangeeta , Burghi, Gastón, Kouatchet, Achille, Mokart, Djamel, Louw, Andry Van de , Lemiale, Virginie , group, on behalf of the EFRAIM investigators and Nine-I study, Bauer, Philippe, Martin-Loeches, Ignacio , Dumas, Guillaume , Pène, Frédéric , Bauer, Philippe R. , Metaxa, Victoria , Montini, Luca , Mokart, Djamel , Azoulay, Élie , group, on behalf of the EFRAIM investigators and Nine-I study

Mayo Clinic

Respiratory Care | April 18, 2023 | Volume: 68 | Issue: 6 | Pages: 740-748

10.4187/respcare.10604 | PMID 37072164 Get It

BACKGROUND: Acute respiratory failure (ARF) remains the most frequent reason for ICU admission in patients who are immunocompromised. This study reports etiologies and outcomes of ARF in subjects with solid tumors. METHODS: This study was a post hoc analysis of the EFRAIM study, a prospective multinational cohort study that included 1611 subjects who were immunocompromised and with ARF admitted to the ICU. Subjects with solid tumors admitted to the ICU with ARF were included in the analysis. RESULTS: Among the subjects from the EFRAIM cohort, 529 subjects with solid tumors (32.8%) were included in the analysis. At ICU admission, the median (interquartile range) Sequential Organ Failure Assessment score was 5 (3–9). The types of solid tumor were mostly lung cancer ( n = 111, 21%), breast cancer ( n = 52, 9.8%), and digestive cancer ( n = 47, 8.9%). A majority, 379 subjects (71.6%) were full code at ICU admission. The ARF was caused by bacterial or viral infection ( n = 220, 41.6%), extrapulmonary sepsis ( n = 62, 11.7%), or related to cancer or treatment toxicity ( n = 83, 15.7%), or fungal infection ( n = 23, 4.3%). For 63 subjects (11.9%), the ARF etiology remained unknown after an extensive diagnostic workup. The hospital mortality rate was 45.7% ( n = 232/508). Hospital mortality was independently associated with chronic cardiac failure (odds ratio 1.78, 95% CI 1.09–2.92; P = .02), lung cancer (odds ratio 2.50, 95% CI 1.51–4.19; P < .001), day 1 Sequential Organ Failure Assessment score (odds ratio 1.97, 95% CI 1.32-2.96; P < .001). ARF etiologies other than infectious, related to cancer, or treatment toxicity were associated with better outcomes (odds ratio 0.32, 95% CI 0.16–0.61; P < .001). CONCLUSIONS: Infectious diseases remained the most frequent cause of ARF in subjects with solid tumors admitted to the ICU. Hospital mortality was related to severity at ICU admission, previous comorbidities, and ARF etiologies related to non-malignant causes or pulmonary embolism. Lung tumor was also independently associated with higher mortality.
Abstract CT265: Phase 1 dose-escalation study of SGN-TGT monotherapy in patients with advanced malignancies
Garralda, Elena , Oberoi, H.K., Uboha, Nataliya V. , Keenan, Bridget K., Manda, Sudhir, Mehta, Amitkuma, Moskowitz, Alison J. , Ribrag, Vincent, Richards, Donald, Forero-Torres, Andres , Xu, Ping, Ansell, Stephen M. , Fontana, Elisa , Dumbrava, Ecaterina E. , Calvo, Emiliano , Curigliano, Giuseppe , Davar, Diwakar , Keenan, Bridget P. , Lam, Vincent K. L. , Minchom, Anna , Paluri, Ravi Kumar , Ribrag, Vincent , Siu, Lillian L. , Swiecicki, Paul Loren , Wise-Draper, Trisha Michel , Zain, Jasmine

Mayo Clinic

Cancer Research | April 14, 2023 | Volume: 83 | Issue: 8_Supplement | Pages: CT265-CT265

10.1158/1538-7445.am2023-ct265 Get It

Abstract Background: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is an inhibitory immune checkpoint receptor expressed on subsets of T-cells and natural killer (NK) cells. TIGIT inhibits T and NK cell function by binding to CD155 and CD112. SEA-TGT is an investigational human, nonfucosylated monoclonal antibody directed against TIGIT, blocking TIGIT's interaction with CD155 and CD112. SGNTGT-001 (NCT04254107) is a phase 1, open-label, multicenter study of SEA-TGT in patients (pts) with advanced malignancies (solid tumors and lymphomas). In this abstract, we present data from the dose-escalation phase (Part A). Methods: Pts received SEA-TGT ranging from 0.01 to 6.0 mg/kg of body weight intravenously every 3 weeks (Q3W). The primary objectives were to evaluate the safety and tolerability of SEA-TGT and identify the maximum tolerated dose (MTD) or the recommended dose and schedule of SEA-TGT. The optimal biological dose was defined using the Clinical Utility Index. Secondary objectives included the evaluation of antitumor activity, pharmacokinetics (PK) and immunogenicity. Antitumor activity was based on Response Evaluation Criteria in Solid Tumors version 1.1 or the Lugano classification criteria with Lymphoma Response to Immunomodulatory Therapy Criteria. Results: From June 12, 2020, to October 5, 2022, 41 pts were enrolled (2, 4, 5, 11, 12, and 7 pts in the 0.01, 0.1, 0.3, 1, 3, and 6 mg/kg cohorts, respectively). Among the 39 pts who were treated 23 pts had solid tumors and 16 had lymphomas. The median number of prior therapies across all cohorts was 5. Treatment emergent adverse events of any grade were reported in 100% of pts, and treatment-related adverse events (TRAEs) of any grade were reported in 69.2%. TRAEs seen in ≥10% of the pts were infusion-related reaction (38.5%), chills (25.6%), pyrexia (17.9%), fatigue (12.8%), maculopapular rash (12.8%), and rash (10.3%). Seven pts (17.9%) reported TRAEs grade ≥3, and rash (5.1%) was the most frequently reported. No grade 4 or 5 TRAEs were reported. One dose-limiting toxicity, pruritic rash, was observed in 1 pt in the 6 mg/kg cohort, and MTD was not exceeded. Based on the PK and pharmacodynamic data, 1 mg/kg Q3W was selected as the optimal biological dose for the expansion cohorts. One partial response was observed in a pt with gastric cancer, and 2 partial metabolic responses were seen in a pt with Hodgkin’s lymphoma and a pt with diffuse large B-cell lymphoma. Conclusions: Overall, clinical data for SEA-TGT from the SGNTGT-001 trial suggest a manageable and tolerable safety profile. Preliminary antitumor activity warrants further clinical evaluation of SEA-TGT. SGNTGT-001 is ongoing and evaluating monotherapy and combination therapies. Citation Format: Elena Garralda Cabanas, Elisa Fontana, Honey Kumar Oberoi, Nataliya V. Uboha, Ecaterina E. Dumbrava, Emiliano Calvo, Giuseppe Curigliano, Diwakar Davar, Bridget K. Keenan, Vincent K. Lam, Sudhir Manda, Amitkuma Mehta, Anna Minchom, Alison Moskowitz, Ravi Paluri, Vincent Ribrag, Donald Richards, Lillian Siu, Paul Swiecicki, Trisha Wise-Draper, Jasmine Zain, Andres Forero-Torres, Ping Xu, Stephen Ansell. Phase 1 dose-escalation study of SGN-TGT monotherapy in patients with advanced malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT265.
Needs-based novel digital curriculum for the neuromodulation training deficit: Pain Rounds
Durbhakula, Shravani , Toy, Serkan , Acosta, C. , Barman, Ross , Kelner, Andrew F, Issa, Mohammad A. , Broachwala, Mustafa , Marascalchi, Bryan J. , Navalgund, Yeshvant A, Pak, Daniel , Petersen, Erika , Moeschler, Susan M. , Kohan, Lynn , Barman, Ross A , Mehta, Neel D , Kohan, Lynn R , Acosta, Carlos A

Mayo Clinic

Regional Anesthesia & Pain Medicine | April 13, 2023 | Volume: 48 | Issue: 8 | Pages: 414-419

10.1136/rapm-2023-104480 | PMID 37055185 Get It

This study reports the needs-based development, effectiveness and feasibility of a novel, comprehensive spinal cord stimulation (SCS) digital curriculum designed for pain medicine trainees. The curriculum aims to address the documented systematic variability in SCS education and empower physicians with SCS expertise, which has been linked to utilization patterns and patient outcomes. Following a needs assessment, the authors developed a three-part SCS e-learning video curriculum with baseline and postcourse knowledge tests. Best practices were used for educational video production and test-question development. The study period was from 1 February 2020 to 31 December 2020. A total of 202 US-based pain fellows across two cohorts (early-fellowship and late-fellowship) completed the baseline knowledge assessment, while 122, 96 and 88 participants completed all available post-tests for Part I (Fundamentals), Part II (Cadaver Lab) and Part III (Decision Making, The Literature and Critical Applications), respectively. Both cohorts significantly increased knowledge scores from baseline to immediate post-test in all curriculum parts (p<0.001). The early-fellowship cohort experienced a higher rate of knowledge gain for Parts I and II (p=0.045 and p=0.027, respectively). On average, participants viewed 6.4 out of 9.6 hours (67%) of video content. Self-reported prior SCS experience had low to moderate positive correlations with Part I and Part III pretest scores (r=0.25, p=0.006; r=0.37, p<0.001, respectively). Initial evidence suggests that Pain Rounds provides an innovative and effective solution to the SCS curriculum deficit. A future controlled study should examine this digital curriculum’s long-term impact on SCS practice and treatment outcomes.
Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy
Driver‐Dunckley, Erika , Dunckley, Nathaniel, Sue, Lucia I., Shill, Holly A. , Mehta, Shyamal H. , Belden, Christine M. , Tremblay, Cécilia , Beach, Thomas G. , Driver-Dunckley, Erika D., Zhang, Nan , Serrano, Geidy E. , Atri, Alireza , Adler, Charles H.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | April 11, 2023 | Volume: 82 | Issue: 5 | Pages: 438-451

10.1093/jnen/nlad025 | PMID 37040756 Get It

Abstract The objective of this study was to determine the prevalence, incidence, and clinical diagnostic accuracy for neuropathologically diagnosed progressive supranuclear palsy (PSP) with data from a longitudinal clinicopathological study using Rainwater criteria to define neuropathological PSP. Of 954 autopsy cases, 101 met Rainwater criteria for the neuropathologic diagnosis of PSP. Of these, 87 were termed clinicopathological PSP as they also had either dementia or parkinsonism or both. The prevalence of clinicopathologically defined PSP subjects in the entire autopsy dataset was 9.1%, while the incidence rate was estimated at 780 per 100 000 persons per year, roughly 50-fold greater than most previous clinically determined PSP incidence estimates. A clinical diagnosis of PSP was 99.6% specific but only 9.2% sensitive based on first examination, and 99.3% specific and 20.7% sensitive based on the final clinical exam. Of the clinicopathologically defined PSP cases, 35/87 (∼40%) had no form of parkinsonism at first assessment, while this decreased to 18/83 (21.7%) at final assessment. Our study confirms a high specificity but low sensitivity for the clinical diagnosis of PSP. The low clinical sensitivity for PSP is likely primarily responsible for previous underestimates of the PSP population incidence rate.
RIGHT VENTRICULAR DYSFUNCTION IN SEPSIS: AN UPDATED NARRATIVE REVIEW
Bansal, Mridul , Mehta, Aryan , Balakrishna, Akshay Machanahalli, Sundaram, Arvind Kalyan, Kanwar, Ardaas, Singh, Mandeep, Vallabhajosyula, Saraschandra , Vallabhajosyula, Saraschandra

Mayo Clinic

Shock | March 21, 2023 | Volume: 59 | Issue: 6 | Pages: 829-837

10.1097/shk.0000000000002120 | PMID 36943772 Get It

ABSTRACT Sepsis is a multisystem disease process, which constitutes a significant public health challenge and is associated with high morbidity and mortality. Among other systems, sepsis is known to affect the cardiovascular system, which may manifest as myocardial injury, arrhythmias, refractory shock, and/or septic cardiomyopathy. Septic cardiomyopathy is defined as the reversible systolic and/or diastolic dysfunction of one or both ventricles. Left ventricle dysfunction has been extensively studied in the past, and its prognostic role in patients with sepsis is well documented. However, there is relatively scarce literature on right ventricle (RV) dysfunction and its role. Given the importance of timely detection of septic cardiomyopathy and its bearing on prognosis of patients, the role of RV dysfunction has come into renewed focus. Hence, through this review, we sought to describe the pathophysiology of RV dysfunction in sepsis and what have we learnt so far about its multifactorial nature. We also elucidate the roles of different biomarkers for its detection and prognosis, along with appropriate management of such patient population.